Linlin Lv

650 total citations
30 papers, 433 citations indexed

About

Linlin Lv is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Linlin Lv has authored 30 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Linlin Lv's work include Ubiquitin and proteasome pathways (5 papers), Cancer-related gene regulation (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Linlin Lv is often cited by papers focused on Ubiquitin and proteasome pathways (5 papers), Cancer-related gene regulation (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Linlin Lv collaborates with scholars based in China. Linlin Lv's co-authors include Deshi Dong, Xiaohan Zhai, Huijian Wu, Xufeng Tao, Xu Han, Lingli Zheng, Yan Qi, Youwei Xu, Lina Xu and Jinyong Peng and has published in prestigious journals such as Chemosphere, Frontiers in Immunology and Molecules.

In The Last Decade

Linlin Lv

28 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Linlin Lv China 12 234 93 73 39 34 30 433
Marta Hałas‐Wiśniewska Poland 11 231 1.0× 76 0.8× 60 0.8× 37 0.9× 21 0.6× 32 466
Shuo Yu China 9 197 0.8× 97 1.0× 84 1.2× 20 0.5× 31 0.9× 14 401
Jun‐Ping Shiau Taiwan 11 252 1.1× 78 0.8× 79 1.1× 31 0.8× 20 0.6× 44 463
Jianlin Ren China 9 326 1.4× 127 1.4× 115 1.6× 42 1.1× 22 0.6× 18 578
Weixue Huang China 13 342 1.5× 85 0.9× 38 0.5× 37 0.9× 42 1.2× 39 544
Sameer Ullah Khan India 11 270 1.2× 121 1.3× 125 1.7× 51 1.3× 27 0.8× 20 545
Heon‐Woo Lee South Korea 15 279 1.2× 69 0.7× 76 1.0× 41 1.1× 42 1.2× 31 595
Luo Jiang China 15 247 1.1× 70 0.8× 84 1.2× 19 0.5× 25 0.7× 29 553

Countries citing papers authored by Linlin Lv

Since Specialization
Citations

This map shows the geographic impact of Linlin Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linlin Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linlin Lv more than expected).

Fields of papers citing papers by Linlin Lv

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linlin Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linlin Lv. The network helps show where Linlin Lv may publish in the future.

Co-authorship network of co-authors of Linlin Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Linlin Lv. A scholar is included among the top collaborators of Linlin Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linlin Lv. Linlin Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Yu, Fangyue Guo, Linlin Lv, et al.. (2025). Targeted inhibitors of S100A9 alleviate chronic pancreatitis by inhibiting M2 macrophage polarization via the TAOK3-JNK signaling pathway. Frontiers in Immunology. 16. 1526813–1526813. 1 indexed citations
2.
Han, Jinming, Xiaohan Zhai, Yunming Li, et al.. (2025). Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database. Breast Cancer Research. 27(1). 54–54. 2 indexed citations
3.
Lv, Linlin, Shujing Li, Jie Kang, et al.. (2024). Inhibition of ABI2 ubiquitination-dependent degradation suppresses TNBC cell growth via down-regulating PI3K/Akt signaling pathway. Cancer Cell International. 24(1). 222–222. 2 indexed citations
4.
Wang, Xinying, et al.. (2023). Borneol-modified PEGylated graphene oxide as a nanocarrier for brain-targeted delivery of ginsenoside Rg1 against depression. International Journal of Pharmaceutics. 643. 123284–123284. 17 indexed citations
5.
6.
Wang, Xinying, et al.. (2023). Catechol chitosan coated dual-loaded liposomes based on oxidation and saccharification mechanisms for enhancing skin anti-aging effects. International Journal of Biological Macromolecules. 256(Pt 2). 128342–128342. 5 indexed citations
7.
Xia, Kangkai, Shujing Li, Yuxi Yang, et al.. (2023). Cryptochrome 2 acetylation attenuates its antiproliferative effect in breast cancer. Cell Death and Disease. 14(4). 250–250. 11 indexed citations
8.
Huo, Wei, Xiaomin Yu, Xiaoxia Shi, et al.. (2023). USP13 promotes breast cancer metastasis through FBXL14-induced Twist1 ubiquitination. Cellular Oncology. 46(3). 717–733. 10 indexed citations
9.
Zhai, Xiaohan, Xufeng Tao, Shilei Yang, et al.. (2023). Success stories of natural product-derived compounds from plants as multidrug resistance modulators in microorganisms. RSC Advances. 13(12). 7798–7817. 14 indexed citations
10.
Yang, Yuxi, Shujing Li, Yulin Li, et al.. (2023). α-Catenin acetylation is essential for its stability and blocks its tumor suppressor effects in breast cancer through Yap1. Cancer Gene Therapy. 30(12). 1624–1635.
11.
Zhou, Qi, Xufeng Tao, Fangyue Guo, et al.. (2023). Tryptophan metabolite norharman secreted by cultivated Lactobacillus attenuates acute pancreatitis as an antagonist of histone deacetylases. BMC Medicine. 21(1). 329–329. 18 indexed citations
12.
13.
Tao, Xufeng, Xiaohan Zhai, Yanna Zhu, et al.. (2023). Application of aptamer-drug delivery system in the therapy of breast cancer. Biomedicine & Pharmacotherapy. 161. 114444–114444. 42 indexed citations
14.
15.
Lv, Linlin, Jiaqi Ren, Hao Yu, et al.. (2023). Advances in targeted therapy for pancreatic cancer. Biomedicine & Pharmacotherapy. 168. 115717–115717. 9 indexed citations
16.
Xiang, Hong, et al.. (2022). Metabolic reprogramming of immune cells in pancreatic cancer progression. Biomedicine & Pharmacotherapy. 157. 113992–113992. 42 indexed citations
17.
Lv, Linlin, Yanna Zhu, Xiaohan Zhai, et al.. (2022). Relationship between metabolic reprogramming and drug resistance in breast cancer. Frontiers in Oncology. 12. 942064–942064. 25 indexed citations
18.
Li, Shuai, Jingyuan Zhao, Linlin Lv, & Deshi Dong. (2021). Identification and Validation of TYMS as a Potential Biomarker for Risk of Metastasis Development in Hepatocellular Carcinoma. Frontiers in Oncology. 11. 762821–762821. 7 indexed citations
19.
20.
Lv, Linlin, Lingli Zheng, Deshi Dong, et al.. (2013). Dioscin, a natural steroid saponin, induces apoptosis and DNA damage through reactive oxygen species: A potential new drug for treatment of glioblastoma multiforme. Food and Chemical Toxicology. 59. 657–669. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marta Hałas‐Wiśniewska Breakdown of academic impact, for papers by Shuo Yu Breakdown of academic impact, for papers by Jun‐Ping Shiau Breakdown of academic impact, for papers by Jianlin Ren Breakdown of academic impact, for papers by Weixue Huang Breakdown of academic impact, for papers by Sameer Ullah Khan Breakdown of academic impact, for papers by Heon‐Woo Lee Breakdown of academic impact, for papers by Luo Jiang
Rankless by CCL
2026